# Anidulafungin (Eraxis)

> Echinocandin lipopeptide for invasive Candida infections.

Source: https://peptides.cafe/peptide/anidulafungin
Category: Echinocandin · Antifungal
Tag: FDA-Approved · Antifungal

## Mechanism
Semisynthetic lipopeptide that non-competitively inhibits β-(1,3)-D-glucan synthase, disrupting fungal cell wall synthesis in Candida and Aspergillus species.

## Research areas
- Candidemia and other invasive candidiasis
- Esophageal candidiasis

## Common research protocols
- IV daily: 200 mg IV loading dose, then 100 mg IV daily.

## Study summaries
- "Anidulafungin vs fluconazole in invasive candidiasis" — NEJM (2007): Superior clinical response in invasive candidiasis.

## Considerations
- FDA-approved.
- No dose adjustment for renal/hepatic impairment.
- Infusion-related reactions possible.

## Disclaimer
Educational content only. Not medical advice, diagnosis, or treatment. Most research peptides are not FDA-approved for human therapeutic use. Consult a licensed clinician before any use.